| Cost-effectiveness of alemtuzumab in the treatment of relapsing forms of multiple sclerosis in the United States V Chirikov, I Ma, N Joshi, D Patel, A Smith, C Giambrone, N Cornelio, ... Value in Health 22 (2), 168-176, 2019 | 36 | 2019 |
| Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States V Chirikov, I Ma, N Joshi, D Patel, A Smith, C Giambrone, N Cornelio, ... Value in Health 22 (2), 168-176, 2019 | 34 | 2019 |
| Relationship between depression and physical activity, disability, burden, and health-related quality of life among patients with arthritis N Joshi, R Khanna, RM Shah Population health management 18 (2), 104-114, 2015 | 33 | 2015 |
| Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma M Elsawy, JC Chavez, I Avivi, JF Larouche, L Wannesson, K Cwynarski, ... Blood, The Journal of the American Society of Hematology 140 (21), 2248-2260, 2022 | 32 | 2022 |
| Patient and caregiver benefit-risk preferences for non-metastatic castration-resistant prostate cancer treatment (nmCRPC). S Srinivas, AF Mohamed, S Appukkuttan, M Botteman, X Ng, N Joshi, ... Journal of Clinical Oncology 37 (27_suppl), 196-196, 2019 | 28* | 2019 |
| Treatment patterns and healthcare resource utilization among patients with hereditary angioedema in the United States MA Riedl, A Banerji, ME Manning, E Burrell, N Joshi, D Patel, T Machnig, ... Orphanet journal of rare diseases 13 (1), 1-7, 2018 | 19 | 2018 |
| Under-use of Hypomethylating Agents in Patients With Higher-risk Myelodysplastic Syndrome in the United States: A Large Population-based Analysis S Corman, N Joshi, T Wert, H Kale, K Hill, AM Zeidan Clinical Lymphoma Myeloma and Leukemia 21 (2), e206-e211, 2021 | 18 | 2021 |
| Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients … M Elsawy, JC Chavez, I Avivi, JF Larouche, L Wannesson, K Cwynarski, ... Blood 138, 430, 2021 | 15 | 2021 |
| Physician preferences for non-metastatic castration-resistant prostate cancer treatment S Srinivas, AF Mohamed, S Appukkuttan, M Botteman, X Ng, N Joshi, ... BMC urology 20 (1), 1-10, 2020 | 15 | 2020 |
| Health State Utilities for Acute Myeloid Leukaemia: A Time Trade-off Study N Joshi, M Hensen, S Patel, W Xu, K Lasch, E Stolk PharmacoEconomics 37 (1), 85-92, 2019 | 14 | 2019 |
| Injectable Hypomethylating Agents for Management of Myelodysplastic Syndromes: Patients’ Perspectives on Treatment AM Zeidan, S Jayade, J Schmier, M Botteman, A Hassan, D Ruiters, K Hill, ... Clinical Lymphoma Myeloma and Leukemia 22 (3), e185-e198, 2022 | 12 | 2022 |
| Direct Medical Costs Associated With Treatment Nonpersistence in Patients With Higher-Risk Myelodysplastic Syndromes Receiving Hypomethylating Agents: A Large Retrospective … N Joshi, H Kale, S Corman, T Wert, K Hill, AM Zeidan Clinical Lymphoma Myeloma and Leukemia 21 (3), e248-e254, 2021 | 9 | 2021 |
| Patient-reported outcomes in schizophrenia patients treated with once-monthly extended-release risperidone in a long-term clinical study R Dhanda, D Varghese, VR Nadipelli, M Fava, N Joshi, CT Solem, ... Patient preference and adherence 13, 1037, 2019 | 8 | 2019 |
| Patient and caregiver preferences for haemophilia A treatments: A discrete choice experiment J Su, N Li, N Joshi, X Ng, M Botteman, R Shah, N Jain, N Lyn, R Preblick Haemophilia 26 (6), e291-e299, 2020 | 5 | 2020 |
| Physician benefit-risk preferences for non-metastatic castration-resistant prostate cancer treatment (nmCRPC). S Srinivas, AF Mohamed, S Appukkuttan, M Botteman, X Ng, N Joshi, ... Journal of Clinical Oncology 37 (15_suppl), e16610-e16610, 2019 | 4 | 2019 |
| Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes AM Zeidan, N Joshi, H Kale, WJ Wang, S Corman, T Salimi, RS Epstein Clinical Lymphoma Myeloma and Leukemia 22 (9), 670-679, 2022 | 3 | 2022 |
| Evaluation of minimal important difference and responder definition in the EORTC QLQ-PAN26 module for assessing health-related quality of life in patients with surgically … M Reni, J Braverman, A Hendifar, CP Li, T Macarulla, DY Oh, H Riess, ... Annals of surgical oncology, 1-10, 2021 | 3 | 2021 |
| Evaluation of minimal important difference (MID) for the European organisation for research and treatment of cancer (EORTC) pancreatic cancer module (PAN26) in patients with … M Reni, J Braverman, A Hendifar, CP Li, TM Mercade, DY Oh, H Riess, ... Annals of Oncology 30, v262, 2019 | 3 | 2019 |
| Patient-Reported Outcomes (PROs) in Zuma-7, a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC … M Elsawy, JC Chavez, I Avivi, JF Larouche, L Wannesson, K Cwynarski, ... 2022 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT …, 2022 | 2 | 2022 |
| Cost-Effectiveness of Alemtuzumab In The Treatment of Relapsing Forms of Multiple Sclerosis In The United States and Societal Spillover Effects V Chirikov, I Ma, N Joshi, D Patel, A Smith, C Giambrone, N Cornelio, ... Value in Health 20 (9), A722, 2017 | 2 | 2017 |
